These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38543552)

  • 41. Trajectory of Humoral Responses to Two Doses of ChAdOx1 nCoV-19 Vaccination in Patients Receiving Maintenance Hemodialysis.
    Ling TC; Chen PL; Li NY; Ko WC; Sun CY; Chao JY; Shieh CC; Shen CF; Wu JL; Huang TC; Chao CH; Wang JR; Chang YT
    Microbiol Spectr; 2023 Feb; 11(2):e0344522. PubMed ID: 36809164
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunogenicity and safety of heterologous booster with protein-based COVID-19 vaccine (NVX-CoV2373) in healthy adults: A comparative analysis with mRNA vaccines.
    Sheng WH; Lin PH; Cheng YC; Wu YY; Hsieh MJ; Yang HC; Chang SY; Chang SC
    J Formos Med Assoc; 2024 Mar; 123(3):340-346. PubMed ID: 37996322
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV.
    Zhao G; Du L; Ma C; Li Y; Li L; Poon VK; Wang L; Yu F; Zheng BJ; Jiang S; Zhou Y
    Virol J; 2013 Aug; 10():266. PubMed ID: 23978242
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pseudovirus-Based Assays for the Measurement of Antibody-Mediated Neutralization of SARS-CoV-2.
    Balinsky C; Jani V; Sun P; Williams M; Defang G; Porter KR
    Methods Mol Biol; 2022; 2452():361-378. PubMed ID: 35554917
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Measuring Neutralizing Antibodies to SARS-CoV-2 Using Lentiviral Spike-Pseudoviruses.
    Neerukonda SN; Vassell R; Weiss CD; Wang W
    Methods Mol Biol; 2022; 2452():305-314. PubMed ID: 35554914
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of Neutralizing Activity against Omicron Subvariants in BA.5 Breakthrough Infection and Three-Dose Vaccination Using a Novel Chemiluminescence-Based, Virus-Mediated Cytopathic Assay.
    Toyoda M; Tan TS; Motozono C; Barabona G; Yonekawa A; Shimono N; Minami R; Nagasaki Y; Miyashita Y; Oshiumi H; Nakamura K; Matsushita S; Kuwata T; Ueno T
    Microbiol Spectr; 2023 Aug; 11(4):e0066023. PubMed ID: 37310218
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neutralization escape by SARS-CoV-2 Omicron subvariant BA.2.86.
    Lasrado N; Collier AY; Hachmann NP; Miller J; Rowe M; Schonberg ED; Rodrigues SL; LaPiana A; Patio RC; Anand T; Fisher J; Mazurek CR; Guan R; Wagh K; Theiler J; Korber BT; Barouch DH
    Vaccine; 2023 Nov; 41(47):6904-6909. PubMed ID: 37872011
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron.
    Amano M; Otsu S; Uemura Y; Ichikawa Y; Matsumoto S; Higashi-Kuwata N; Matsushita S; Shimada S; Mitsuya H
    Sci Rep; 2023 Oct; 13(1):17404. PubMed ID: 37833390
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Progressive loss of conserved spike protein neutralizing antibody sites in Omicron sublineages is balanced by preserved T cell immunity.
    Muik A; Lui BG; Quandt J; Diao H; Fu Y; Bacher M; Gordon J; Toker A; Grosser J; Ozhelvaci O; Grikscheit K; Hoehl S; Kohmer N; Lustig Y; Regev-Yochay G; Ciesek S; Beguir K; Poran A; Vogler I; Türeci Ö; Sahin U
    Cell Rep; 2023 Aug; 42(8):112888. PubMed ID: 37527039
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants.
    Seki Y; Yoshihara Y; Nojima K; Momose H; Fukushi S; Moriyama S; Wagatsuma A; Numata N; Sasaki K; Kuzuoka T; Yato Y; Takahashi Y; Maeda K; Suzuki T; Mizukami T; Hamaguchi I
    Med; 2022 Jun; 3(6):406-421.e4. PubMed ID: 35815933
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
    Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
    Elife; 2022 Aug; 11():. PubMed ID: 36004719
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immune escape of BA.2.86 is comparable to XBB subvariants from the plasma of BA.5- and BA.5-XBB-convalescent subpopulations.
    Yang X; Wang Y; Liang Z; Cui T; Chen D; Li G; Xu H; Liu S; Zhong N; Huang W; Wang Z
    J Med Virol; 2024 Jan; 96(1):e29417. PubMed ID: 38258345
    [TBL] [Abstract][Full Text] [Related]  

  • 53. XBB.1.5 monovalent booster improves antibody binding and neutralization against emerging SARS-CoV-2 Omicron variants.
    Jain S; Kumar S; Lai L; Linderman S; Malik AA; Ellis ML; Godbole S; Solis D; Sahoo MK; Bechnak K; Paredes I; Tanios R; Kazzi B; Dib SM; Litvack MB; Wimalasena ST; Ciric C; Rostad C; West R; Teng IT; Wang D; Edupuganti S; Kwong PD; Rouphael N; Pinsky BA; Douek DC; Wrammert J; Moreno A; Suthar MS
    bioRxiv; 2024 Feb; ():. PubMed ID: 38370837
    [TBL] [Abstract][Full Text] [Related]  

  • 54. NVX-CoV2373-induced cellular and humoral immunity towards parental SARS-CoV-2 and VOCs compared to BNT162b2 and mRNA-1273-regimens.
    Hielscher F; Schmidt T; Klemis V; Wilhelm A; Marx S; Abu-Omar A; Ziegler L; Guckelmus C; Urschel R; Sester U; Widera M; Sester M
    J Clin Virol; 2022 Dec; 157():105321. PubMed ID: 36279695
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development and effectiveness of pseudotyped SARS-CoV-2 system as determined by neutralizing efficiency and entry inhibition test
    Yang R; Huang B; A R; Li W; Wang W; Deng Y; Tan W
    Biosaf Health; 2020 Dec; 2(4):226-231. PubMed ID: 32864605
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Different Neutralization Profiles After Primary SARS-CoV-2 Omicron BA.1 and BA.2 Infections.
    Medits I; Springer DN; Graninger M; Camp JV; Höltl E; Aberle SW; Traugott MT; Hoepler W; Deutsch J; Lammel O; Borsodi C; Puchhammer-Stöckl E; Zoufaly A; Weseslindtner L; Aberle JH; Stiasny K
    Front Immunol; 2022; 13():946318. PubMed ID: 35928813
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals.
    Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM
    Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rapid Quantification of SARS-CoV-2-Neutralizing Antibodies Using Propagation-Defective Vesicular Stomatitis Virus Pseudotypes.
    Zettl F; Meister TL; Vollmer T; Fischer B; Steinmann J; Krawczyk A; V'kovski P; Todt D; Steinmann E; Pfaender S; Zimmer G
    Vaccines (Basel); 2020 Jul; 8(3):. PubMed ID: 32679691
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Establishment of a pseudovirus neutralization assay based on SARS-CoV-2 S protein incorporated into lentiviral particles.
    Wang S; Liu L; Wang C; Wang Z; Duan X; Chen G; Zhou H; Shao H
    Biosaf Health; 2022 Feb; 4(1):38-44. PubMed ID: 35005601
    [TBL] [Abstract][Full Text] [Related]  

  • 60. SARS-CoV-2 evolves to reduce but not abolish neutralizing action.
    Zhang Y; Ndzouboukou JB; Lin X; Hou H; Wang F; Yuan L; Gan M; Yao Z; Fu H; Cao J; Fan X
    J Med Virol; 2023 Jan; 95(1):e28207. PubMed ID: 36217880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.